Back to Top Skip to main content

Drug-monitoring innovations help providers help their patients

Two Military Health System innovations are helping to ensure best practices for patients with pain, and for patients who’ve been diagnosed with post-traumatic stress disorder. (U.S. Air Force photo by Senior Airman Curt Beach) Two Military Health System innovations are helping to ensure best practices for patients with pain, and for patients who’ve been diagnosed with post-traumatic stress disorder. (U.S. Air Force photo by Senior Airman Curt Beach)

Recommended Content:

Innovation | Substance Abuse | Posttraumatic Stress Disorder | Pain Management | Opioid Safety

FALLS CHURCH, Va. — Two Military Health System innovations are helping to ensure best practices for patients with pain, and for patients who’ve been diagnosed with post-traumatic stress disorder.

The MHS Opioid Registry utilizes cutting-edge technology for data management and reporting to identify patients who’ve been prescribed opioids, said Chris Nichols, the Defense Health Agency’s program manager for Enterprise Intelligence and Data Solutions. Clinical pharmacy professionals, physicians, and other authorized providers can use the patient lookup capability to proactively monitor and manage patients, and intervene as appropriate.

Opioids such as oxycodone, hydrocodone, codeine, and morphine are prescribed to relieve pain. But they are highly addictive, health care experts say, and overuse can lead to death.

The rates of opioid addiction and overdose deaths are lower in the military than among the general population, said Vice Adm. Raquel Bono, DHA director, during a House Armed Service Committee hearing in June on Military Health System reform. Still, she said, the MHS has a role to play.

“Our beneficiaries are no strangers to chronic pain,” Bono said.  “While our primary focus is on our own patient population, we’re also cognizant of the larger public health crisis surrounding opioids. As health professionals and public servants, we have an obligation to help confront that crisis.”

The MHS Opioid Registry was launched in December 2016 and released to all sites in 2017.  Data in the registry includes more than 200 variables including demographics, medications, morphine equivalence daily dose, results of urine drug testing, and opioid risk factors. In the future, MHS Opioid Registry users will also be able to evaluate and track alternative non-opioid therapies for pain management.

Nichols said a registry that’s accessible by both DoD and VA providers and staff is currently under development.

The PTS Provider Prescribing Profile was developed by the DHA’s Pharmacy Operations Division. It lists all providers at military treatment facilities who are treating patients with PTSD or acute stress disorder, said Sushma Roberts, Ph.D., a clinical psychologist and senior program manager for DoD/VA Integrated Behavioral Health, Clinical Communities Support Section, Clinical Support Division. The tool also documents the medications providers are prescribing. 

From February 2000 to June 2018, about 230,000 active-duty service members were diagnosed with PTSD, Roberts said, adding that 75 percent were diagnosed following a deployment of 30 days or longer. 

The clinical practice guideline released in 2017 recommended against prescribing benzodiazepines for PTSD patients, Roberts said. Benzos, also known as tranquilizers, act on the brain and central nervous system to produce a calming effect. People can easily develop a tolerance to benzos, health care experts say, needing higher doses and increased frequency to achieve the same effects. People also may suffer withdrawal symptoms, including insomnia, irritability, anxiety, panic attacks, and seizures.

 “Benzos aren’t necessarily bad,” said Army Lt. Col. Dennis Sarmiento, a psychiatrist and chair of the DHA’s Behavioral Health Clinical Community. “There are indications for their use. Short-term, they can help with anxiety, panic, and sleep. Treating such symptoms can help providers engage patients in care and better establish or reinforce rapport.”

But medications other than benzos are recommended for treating PTSD because they’re more effective, Sarmiento said. For example, antidepressants such as Zoloft, Paxil, Prozac, and Effexor raise the brain’s level of serotonin, a chemical that reduces symptoms of depression and anxiety. 

They also can be used with trauma-focused psychotherapy, Sarmiento said. Those therapies include talking or writing about traumatic events, or learning and practicing meditation or deep-breathing exercises to manage anxiety.

Sarmiento notes that throughout the MHS, benzo prescriptions have been on a downward trend since peaking in 2012.

According to the tool, the number of benzos prescriptions for MHS beneficiaries diagnosed with PTSD dropped from 1,922 in the first quarter of fiscal year 2017 to 1,622 for second quarter of FY 2018.

You also may be interested in...

Department of Defense Serum Repository

Infographic
8/3/2016
The Department of Defense Serum Repository is a longitudinal serum repository that serves as a central archive of sera drawn from Service members for medical surveillance purposes. As the world’s largest repository of its kind, the DoDSR has greatly contributed to a better understanding of the etiology of health conditions that would otherwise not be amenable to prospective study.  More on the DODSR  •	The DoDSR stores more than 60 million serial serum specimens from more than 10 million active duty and reserve service members throughout their careers. •	Since 1990, sera remaining after routine HIV-1 antibody testing and sera collected before and after major deployments have been forwarded to the DoDSR. •	All serial serum specimens stored in the DoDSR are linkable to data in the Defense Medical Surveillance System (DMSS) – the central repository of military and medical surveillance data of U.S. service members. •	At the repository, specimens are stored in precisely documented locations in walk-in freezers at -30 Celsius. •	The DoDSR adds a powerful sero epidemiological capability to overall military health surveillance with linkage of data relevant to individual characteristics, exposure states, medical events, and specimens. •	As a result, studies that used to require months to years, if feasible and affordable at all, can now be conducted in days to weeks by in-house epidemiologists.  Over time, the serum repository will increase in its value as new etiologic hypotheses are developed, as technologies for detecting biological markers in sera are improved, and as medical events accrue among aging cohorts of contributors. Follow us on Twitter for more info: @AFHSBPAGE

The Department of Defense Serum Repository is a longitudinal serum repository that serves as a cental archive of sera drawn from Service members for medical surveillance purposes.

Recommended Content:

Armed Forces Health Surveillance Branch | DoD Serum Repository | Innovation

DCOE Annual Report 2014

Report
7/16/2015

Annual Report for the Defense Center of Excellence - 2014

Recommended Content:

Cognitive Rehabilitation Therapy | Mental Health Care | Traumatic Brain Injury | Posttraumatic Stress Disorder | Suicide Prevention | DoD/VA Sharing Initiatives | Deployment Health

2013 MHS Innovation Report

Report
3/3/2014

2013 Military Health System Innovation Report. This report contains information about MHS innovations in clinical care, research and development, and healthcare management. It also provides an overview of the MHS Innovation Program and information on the future of MHS innovation.

Recommended Content:

Innovation | Innovation | Innovation | Access, Cost, Quality, and Safety | Technology

DoD Instruction 1010.04: Problematic Substance Use by DoD Personnel

Policy

Establishes policies, assigns responsibilities, and prescribes procedures for problematic alcohol and drug use prevention, identification, diagnosis, and treatment for DoD military and civilian personnel.

  • Identification #: DoD Instruction 1010.04
  • Date: 2/20/2014
  • Type: Instructions
  • Topics: Substance Abuse

Waiver of Restrictive Licensure and Privileging Procedures to Facilitate the Expansion of Telemedicine Services in the Military Health System 12-010

Policy

In order to facilitate the expansion of telemedicine services in the Military Health System, this memorandum waives selective provisions of Department of Defense 602S.13-R, "Clinical Quality Assurance in the Military Health System," June 11 , 2004. This waiver is conditioned on the specific provisions of this memorandum, and shall remain in effect, unless modified or revoked, until the cancellation and reissuance of DoD 602S.13-R, or the issuance of a Department of Defense Instruction for or including telemedicine.

Planning for the Reform of the Governance of the Military Health System

Policy
  • Identification #: N/A
  • Date: 3/2/2012
  • Type: Guidelines
  • Topics: Innovation

Guidance for Providers Prescribing Atypical Antipsychotic Medication 12-003

Policy

Articles in popular media, and the concern of several national and military leaders in recent months, have raised the question of whether certain psychoactive medications are inappropriately prescribed for post-traumatic stress disorder (PTSD) and commonly comorbid conditions.

<< < 1 2 3 4 > >> 
Showing results 46 - 53 Page 4 of 4

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing; Download a PDF Reader or learn more about PDFs.